A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors

Status Active, not recruiting

Clinical Trial Summary

This phase I, first-in-human, open-label clinical study will evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of HLX53 (an anti-TIGIT Fc fusion protein) in patients with advanced/metastatic solid tumors.

Clinical Trial Description

This study is an open-label phase I clinical study to evaluate the safety, tolerability , PK/PD and preliminary efficacy of HLX53 in patients with advanced/metastatic solid tumor. 11-30 subjects with advanced or metastatic solid tumors will be enrolled. The accelerated titration and traditional 3 + 3 dose escalation design will be implemented. Subjects will receive intravenous infusion of HLX53 at different doses according to the order of enrollment. There are 5 preset dose groups, namely 30mg/QW, 150mg/QW, 400mg/QW, 1000mg/Q3W and 2000mg/Q3W, administered by intravenous infusion. Observation period of DLT will last for 21 days after the first administration of HLX53. Maximum tolerated dose (MTD) definition: The highest dose level at which no more than 1 of 6 DLT-evaluable subjects developed DLT. At the MTD dose, at least 6 subjects were evaluable for DLT. When the MTD is determined, the MTD is usually used as the RP2D, or the RP2D is determined based on safety, PK/PD/ADA/NAb characteristics, and potential clinical efficacy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05394168
Study type	Interventional
Source	Shanghai Henlius Biotech
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	December 9, 2022
Completion date	March 4, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05514444` - Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)	Phase 1
Active, not recruiting	`NCT04501276` - A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients	Phase 1
Active, not recruiting	`NCT04182516` - Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors	Phase 1
Terminated	`NCT00996255` - Dose-Escalation Study of PHA-793887 in Patients With Advanced/Metastatic Solid Tumors	Phase 1
Terminated	`NCT02444793` - A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors	Phase 1
Recruiting	`NCT03526835` - A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT05718895` - A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors	Phase 1
Completed	`NCT03833427` - Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)	Phase 1
Recruiting	`NCT04645069` - ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT05607498` - First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma	Phase 1
Recruiting	`NCT05405595` - ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors	Phase 1/Phase 2
Completed	`NCT02665416` - Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors	Phase 1
Terminated	`NCT01092052` - Study of NMS-1116354 in Advanced/Metastatic Solid Tumors	Phase 1
Completed	`NCT05277402` - ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors	Phase 1
Recruiting	`NCT05614258` - Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors	Phase 1